Literature DB >> 21791602

Balanced interactions between Lyn, the p85alpha regulatory subunit of class I(A) phosphatidylinositol-3-kinase, and SHIP are essential for mast cell growth and maturation.

Peilin Ma1, Sasidhar Vemula, Veerendra Munugalavadla, Jinbiao Chen, Emily Sims, Jovencio Borneo, Takako Kondo, Baskar Ramdas, Raghuveer Singh Mali, Shuo Li, Eri Hashino, Clifford Takemoto, Reuben Kapur.   

Abstract

The growth and maturation of bone marrow-derived mast cells (BMMCs) from precursors are regulated by coordinated signals from multiple cytokine receptors, including KIT. While studies conducted using mutant forms of these receptors lacking the binding sites for Src family kinases (SFKs) and phosphatidylinositol-3-kinase (PI3K) suggest a role for these signaling molecules in regulating growth and survival, how complete loss of these molecules in early BMMC progenitors (MCps) impacts maturation and growth during all phases of mast cell development is not fully understood. We show that the Lyn SFK and the p85α subunit of class I(A) PI3K play opposing roles in regulating the growth and maturation of BMMCs in part by regulating the level of PI3K. Loss of Lyn in BMMCs results in elevated PI3K activity and hyperactivation of AKT, which accelerates the rate of BMMC maturation due in part to impaired binding and phosphorylation of SHIP via Lyn's unique domain. In the absence of Lyn's unique domain, BMMCs behave in a manner similar to that of Lyn- or SHIP-deficient BMMCs. Importantly, loss of p85α in Lyn-deficient BMMCs not only represses the hyperproliferation associated with the loss of Lyn but also represses their accelerated maturation. The accelerated maturation of BMMCs due to loss of Lyn is associated with increased expression of microphthalmia-associated transcription factor (Mitf), which is repressed in MCps deficient in the expression of both Lyn and p85α relative to controls. Our results demonstrate a crucial interplay of Lyn, SHIP, and p85α in regulating the normal growth and maturation of BMMCs, in part by regulating the activation of AKT and the expression of Mitf.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21791602      PMCID: PMC3187372          DOI: 10.1128/MCB.05750-11

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  49 in total

1.  Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance.

Authors:  K Takeda; C Takemoto; I Kobayashi; A Watanabe; Y Nobukuni; D E Fisher; M Tachibana
Journal:  Hum Mol Genet       Date:  2000-01-01       Impact factor: 6.150

2.  Structure-function analysis of Lyn kinase association with lipid rafts and initiation of early signaling events after Fcepsilon receptor I aggregation.

Authors:  M Kovárová; P Tolar; R Arudchandran; L Dráberová; J Rivera; P Dráber
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  The role of SHIP in mast cell degranulation and IgE-induced mast cell survival.

Authors:  Michael Huber; Janet Kalesnikoff; Michael Reth; Gerald Krystal
Journal:  Immunol Lett       Date:  2002-06-03       Impact factor: 3.685

4.  Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation.

Authors:  Valentino Parravicini; Massimo Gadina; Martina Kovarova; Sandra Odom; Claudia Gonzalez-Espinosa; Yasuko Furumoto; Shinichiroh Saitoh; Lawrence E Samelson; John J O'Shea; Juan Rivera
Journal:  Nat Immunol       Date:  2002-07-01       Impact factor: 25.606

5.  PI3K-mediated negative feedback regulation of IL-12 production in DCs.

Authors:  Taro Fukao; Masanobu Tanabe; Yasuo Terauchi; Takayuki Ota; Satoshi Matsuda; Tomoichiro Asano; Takashi Kadowaki; Tsutomu Takeuchi; Shigeo Koyasu
Journal:  Nat Immunol       Date:  2002-08-05       Impact factor: 25.606

6.  Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells.

Authors:  B O'Laughlin-Bunner; N Radosevic; M L Taylor; C DeBerry; D D Metcalfe; M Zhou; C Lowell; D Linnekin
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

7.  Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation.

Authors:  Y Kawakami; J Kitaura; A B Satterthwaite; R M Kato; K Asai; S E Hartman; M Maeda-Yamamoto; C A Lowell; D J Rawlings; O N Witte; T Kawakami
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

8.  SHIP's C-terminus is essential for its hydrolysis of PIP3 and inhibition of mast cell degranulation.

Authors:  J E Damen; M D Ware; J Kalesnikoff; M R Hughes; G Krystal
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

9.  Critical roles of c-Kit tyrosine residues 567 and 719 in stem cell factor-induced chemotaxis: contribution of src family kinase and PI3-kinase on calcium mobilization and cell migration.

Authors:  Shuji Ueda; Masao Mizuki; Hirokazu Ikeda; Tohru Tsujimura; Itaru Matsumura; Kazushi Nakano; Hanako Daino; Zen-ichiro Honda Zi; Junko Sonoyama; Hirohiko Shibayama; Hiroyuki Sugahara; Takashi Machii; Yuzuru Kanakura
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

Review 10.  The diverse roles of mast cells.

Authors:  M F Gurish; K F Austen
Journal:  J Exp Med       Date:  2001-07-02       Impact factor: 14.307

View more
  11 in total

1.  ROCK1 functions as a critical regulator of stress erythropoiesis and survival by regulating p53.

Authors:  Sasidhar Vemula; Jianjian Shi; Raghuveer Singh Mali; Peilin Ma; Yan Liu; Philip Hanneman; Karl R Koehler; Eri Hashino; Lei Wei; Reuben Kapur
Journal:  Blood       Date:  2012-08-13       Impact factor: 22.113

2.  Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.

Authors:  Lakshmi Reddy Palam; Raghuveer Singh Mali; Baskar Ramdas; Sridhar Nonavinkere Srivatsan; Valeria Visconte; Ramon V Tiu; Bart Vanhaesebroeck; Axel Roers; Alexander Gerbaulet; Mingjiang Xu; Sarath Chandra Janga; Clifford M Takemoto; Sophie Paczesny; Reuben Kapur
Journal:  JCI Insight       Date:  2018-02-22

3.  Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.

Authors:  Benedikt Bosbach; Ferdinand Rossi; Yasemin Yozgat; Jennifer Loo; Jennifer Q Zhang; Georgina Berrozpe; Katherine Warpinski; Imke Ehlers; Darren Veach; Andrew Kwok; Katia Manova; Cristina R Antonescu; Ronald P DeMatteo; Peter Besmer
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

4.  KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells.

Authors:  Eunice Ching Chan; Yun Bai; Geethani Bandara; Olga Simakova; Erica Brittain; Linda Scott; Kimberly D Dyer; Amy D Klion; Irina Maric; Alasdair M Gilfillan; Dean D Metcalfe; Todd M Wilson
Journal:  Exp Hematol       Date:  2013-06-04       Impact factor: 3.084

5.  SHP2 phosphatase promotes mast cell chemotaxis toward stem cell factor via enhancing activation of the Lyn/Vav/Rac signaling axis.

Authors:  Namit Sharma; Stephanie Everingham; Baskar Ramdas; Reuben Kapur; Andrew W B Craig
Journal:  J Immunol       Date:  2014-04-14       Impact factor: 5.422

6.  GW5074 and PP2 kinase inhibitors implicate nontraditional c-Raf and Lyn function as drivers of retinoic acid-induced maturation.

Authors:  Holly A Jensen; Rodica P Bunaciu; Jeffrey D Varner; Andrew Yen
Journal:  Cell Signal       Date:  2015-03-26       Impact factor: 4.850

7.  Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells.

Authors:  Sebastian Drube; Franziska Weber; Romy Loschinski; Mandy Beyer; Mandy Rothe; Anja Rabenhorst; Christiane Göpfert; Isabel Meininger; Michaela A Diamanti; David Stegner; Norman Häfner; Martin Böttcher; Kirstin Reinecke; Thomas Herdegen; Florian R Greten; Bernhard Nieswandt; Karin Hartmann; Oliver H Krämer; Thomas Kamradt
Journal:  Oncotarget       Date:  2015-03-10

8.  TAK1 and IKK2, novel mediators of SCF-induced signaling and potential targets for c-Kit-driven diseases.

Authors:  Sebastian Drube; Franziska Weber; Christiane Göpfert; Romy Loschinski; Mandy Rothe; Franziska Boelke; Michaela A Diamanti; Tobias Löhn; Julia Ruth; Dagmar Schütz; Norman Häfner; Florian R Greten; Ralf Stumm; Karin Hartmann; Oliver H Krämer; Anne Dudeck; Thomas Kamradt
Journal:  Oncotarget       Date:  2015-10-06

9.  Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors.

Authors:  Y Obata; K Horikawa; T Takahashi; Y Akieda; M Tsujimoto; J A Fletcher; H Esumi; T Nishida; R Abe
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

10.  Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation.

Authors:  Yuuki Obata; Shota Toyoshima; Ei Wakamatsu; Shunichi Suzuki; Shuhei Ogawa; Hiroyasu Esumi; Ryo Abe
Journal:  Nat Commun       Date:  2014-12-10       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.